

# Assessment of Biochemical Changes among Egyptian Women with Increased Body Weight

Mie Afify<sup>1</sup>, Nervana Samy<sup>1\*</sup>, Maha Hashim<sup>1</sup>, Abd El-Maksoud<sup>1</sup> and Omneya Saleh<sup>2</sup>

<sup>1</sup>Biochemistry Department, National Research Centre, Cairo, Egypt

<sup>2</sup>Internal Medicine Department, National Research Centre, Cairo, Egypt

## Abstract

**Purpose:** The aim of this work is to evaluate the relationships between ghrelin and leptin with the metabolic state of overweight and obese participants among Egyptian women.

**Methods:** This study was conducted on 82 participants, their age ranged from 43 to 65 free from cancer or endocrine-related disease (e.g., diabetes) they were divided into three groups according to their body mass index (BMI). Group 1 (G1) with BMI less than 25 Kg/m<sup>2</sup>, Group 2 (G2) with BMI between 25-30 kg/m<sup>2</sup> and Group 3 (G3) with BMI more than 30 Kg/m<sup>2</sup>. Ghrelin and leptin were determined by ELISA technique, Insulin resistance was measured by homeostasis model assessment and lipid profile was determined in all studied groups.

**Results:** Fasting plasma levels of ghrelin were lower in overweight and obese groups compared to normal weight control group; also, there was statistically significant negative correlation of ghrelin levels with leptin, BMI and HOMA. Our results showed that higher concentrations of fasting leptin were found in overweight and obese groups compared with normal weight control group; also, there was statistically significant positive correlation between leptin and other biochemical parameters; insulin, BMI and HOMA.

**Conclusion:** Our results suggest coordinated roles of ghrelin and leptin in the modulation of the obesity and these markers can be of value in assessment of treatment of such cases.

**Keywords:** Ghrelin; Leptin; HOMA; Obesity

## Introduction

Obesity is a condition that results from chronic disruption of energy balance; energy intake continuously exceeds energy expenditure and accumulation of body fat follows [1]. The prevalence of obesity is on the rise and the obesity pandemic is arguably amongst the most serious public health challenges in the world today. Obesity is strongly associated with type 2 diabetes mellitus, hyperlipidemia and cardiovascular disease, and provides significant contributions to ill health in both western and developing countries. Extensive research into the mechanisms of appetite regulation and energy balance has unveiled complex physiological systems behind energy homeostasis, and yielded potential targets for therapeutic intervention in the fight against obesity [2]. It has been reported that the prevalence of obesity in adults is very high in Egypt, as many as 35% of the population has a BMI over 30, particularly among women, also, the prevalence of diabetes and hypertension parallels that of obesity [3].

The hypothalamus is crucial for appetite regulation and energy homeostasis. Afferent signals from peripheral sites such as the gastrointestinal tract and adipose tissues are integrated by complex neuronal networks to produce efferent responses responsible for food intake and energy metabolism. There are numerous hypothalamic appetite regulators. Orexigenic (appetite-stimulating) compounds include neuropeptide Y (NPY), agouti-related peptide (AgRP), ghrelin, orexin and cannabinoids, and anorexigenic (appetite-suppressing) peptides include pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), thyrotropin-releasing hormone (TRH) and corticotrophin-releasing hormone (CRH) [4].

The appetite-stimulating function of ghrelin was identified secondary to its effect on growth hormone (GH) release from somatotroph cells of the anterior pituitary [5]; however, ghrelin is the first known peripheral hormone to display orexigenic effects through its action on the hypothalamic appetite-regulating pathways [6]. In addition, ghrelin is amongst the most powerful of the orexigenic

peptides [7]. While most orexigenic peptides originate from the brain and are only active when injected into the brain, ghrelin is active even with peripheral administration leading to an increase in appetite in rodents and humans [8,9]. Ghrelin activates NPY/AgRP neurons of the hypothalamic arcuate nucleus (ARC) through its receptor [10]. Plasma ghrelin levels inversely correlate with body mass index (BMI). Thus, ghrelin levels are reduced in those who are obese compared to normal body weight controls [11,12]. Recent evidence suggests that diet-induced obesity causes ghrelin resistance by reducing NPY/AgRP responsiveness to plasma ghrelin and suppressing the neuroendocrine ghrelin axis, in an attempt to limit further food intake [13].

Leptin, known as the prototypical adipokine, is a 167-amino acid peptide with a four-helix bundle motif similar to that of acytokine [14]. It is produced primarily in adipose tissue but is expressed in a variety of tissues including the placenta, ovaries, mammary epithelium, bone marrow [15], and lymphoid tissues [16]. Leptin levels are pulsatile and follow a circadian rhythm, with highest levels between midnight and early morning and lowest levels in the early- to mid-afternoon. Specifically, the concentration of circulating leptin may be up to 75.6% higher during the night as compared to afternoon trough levels [17]. The pulsatile characteristics of leptin secretion are similar in obese and lean individuals, except the obese have higher pulse amplitudes [18].

Leptin regulates energy homeostasis and reproductive,

**\*Corresponding author:** Dr. Nervana Samy, Professor of Biochemistry, Biochemistry Department, National research Centre, Cairo, Egypt, E-mail: [nervana91@hotmail.com](mailto:nervana91@hotmail.com)

Received March 27, 2012; Accepted April 18, 2012; Published April 22, 2012

**Citation:** Afify M, Samy N, Hashim M, El-Maksoud A, Saleh O (2012) Assessment of Biochemical Changes among Egyptian Women with Increased Body Weight. J Obes Wt Loss Ther 2:127. doi:10.4172/2165-7904.1000127

**Copyright:** © 2012 Afify M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

neuroendocrine, immune and metabolic; its concentration reflects the amount of energy stored in body fat. Circulating leptin levels are directly proportional to the amount of body fat [19] and fluctuate with acute changes in caloric intake [20]. Leptin controls energy homeostasis and body weight primarily by activating Ob Rb in the hypothalamus [21].

The Ob Rb activate numerous JAK2/STAT3-dependent and – independent signaling pathways that act in coordination as a network to fully mediate leptin’s action. The activation of individual pathways in the leptin signaling network appears to be differentially regulated in discrete subpopulations of ObRb-expressing neurons.

These pathways are also likely to be regulated by various other hormonal, neuronal, and metabolic signals that cross-talk with leptin. Hence, it is important to fully determine whether and how positive and negative regulators of ObRb signaling, metabolic state, and/or neuronal activity regulate leptin signaling networks in a cell/tissue type-specific manner and how activation of these signaling pathways mediates leptin’s effects in humans [22].

### Aim of the Work

The aim of this work is to evaluate the relationships between ghrelin and leptin with the metabolic state of overweight and obese participants among Egyptian women.

### Material and Methods

This study was conducted on 82 participants, their age ranged from 43 to 65 free from cancer or endocrine-related disease (e.g., diabetes) they were divided into three groups according to their body mass index (BMI). Group 1 (G1) with BMI less than 25 Kg/m<sup>2</sup>, Group 2 (G2) with BMI between 25-30 kg/m<sup>2</sup> and Group 3 (G3) with BMI more than 30 Kg/m<sup>2</sup>. BMI was calculated for all groups as body weight (kg) divided by body height squared (m<sup>2</sup>). Insulin resistance was assessed by means of the homeostasis model assessment (HOMA), which was measured by multiplying fasting serum insulin (micro-units per milliliter) and fasting plasma glucose (micromoles per liter) divided by 22.5 [23].

### Methods

-Blood samples were obtained from participants in the morning after a 12-hour overnight fast. Within 1 hour of collection, samples were processed and stored at –70°C.

-Total plasma ghrelin concentrations were measured using a commercial radioimmunoassay (RIA) kit (Phoenix Pharmaceuticals Inc, Belmont, CA) that uses 125I-labeled bioactive ghrelin as a tracer and a polyclonal antibody raised against full-length acylated human ghrelin, as previously described [24].

-Total plasma leptin concentrations were measured using a commercial RIA kit (Linco Research Inc, St Charles, MO) [19].

-Plasma glucose level was estimated by God-PAP enzymatic colorimetric method [25] using Biomerieux test kit, Cat. No.5 127.

- Serum insulin was detected by commercially available radio-immunoassay (Abbott IMx Insulin assay) which is a micro-particle Enzyme Immunoassay [MEIA] for the quantitative measurement of human insulin [26].

-Measurement of lipid profile (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides) by commercial enzymatic methods (Aeroset automated

analyzer, Abbott Laboratories, Abbott IL). LDL cholesterol was calculated by using Friedewald’s formula [27]

### Statistical Analysis

Standard descriptive statistics were used to summarize the data (e.g., means and standard deviations (SD)). To assess between group differences, we used non-parametric testing (Wilcoxon–Mann–Whitney test). Correlation coefficients reported as Spearman rank correlations.

### Results

Clinical features of the women joined this study are summarized in (Table1), by design there were statistical difference between the three groups as regard the BMI. The incidence of hypertension increased among the obese group compared to the control group.

From the (Table 2), over-weight group (G2) and obese group (G3) highly significant reductions (P<0.001) were observed in the level of ghrelin with means + SD (11.6 ± 4.1 ng/ml) and (12.9 ± 8.7 ng/ml) respectively, as compared with normal weight group (G1) (23.7 ± 9.5 ng/ml) and a significantly difference between over-weight group (G2) and obese group (G3) was observed. The level of leptin hormone in sera of over-weight group (G2) were significantly increased with a mean of (25.3 ± 11.6 ng/ml) while the level of leptin hormone in obese group (G3) found to be highly significant increased with a mean (35.8 ± 16.4 ng/ml), as compared with normal weight group (G1) (12.6 ± 8.2 ng/ml). A significant difference between over-weight group (G2) and obese group (G3) was observed.

Table 3 shows the levels of blood glucose, insulin and insulin resistance in studied groups. The glucose, insulin and insulin resistance concentrations in the sera of over-weight group (G2), obese group (G3) and normal weight group (G1) showed no statistically significant difference (p>0.05) between three groups with means of (86.8 ± 13.9

	Normal weight group (G1)	Over weight group (G2)	Obese group (G3)
number	25	28	29
Age (years)	43-65 49 + 1.5	44-64 50 + 1.9	43-65 49 + 1.2
BMI (Kg/m <sup>2</sup> )	22.15 + 0.91	28.3 + 1.43*	33.43 + 1.65*
Hypertension	2/25	5/28	11/29*

\*Statistical significant compared to the control group P<0.05

Table 1: Demographic data in the different studied groups.

Groups	Ghrelin (ng/ml)	leptin (ng/ml)
<b>Group 1</b>		
No.	25	25
Range	8.6- 48.7	1.3 – 34.7
Mean + SD	23.7 + 9.5	12.6 + 8.2
<b>Group 2</b>		
No.	28	28
Range	4.3 – 21.1	2.4 – 44.1
Mean + SD	11.6 + 4.1	25.3 + 11.6
<b>Group 3</b>		
No.	29	29
Range	3.4 –48.9	7.4 – 69.7
Mean + SD	12.9 + 8.7	35.8 + 16.4
<b>P value</b>		
G1 : G2	<0.001*	<0.05*
G2 : G3	<0.05*	<0.05*
G1 : G3	<0.001*	<0.001*

Table 2: Serum levels of human ghrelin and leptin in different groups.

Groups	Blood glucose(mg/dl)	Insulin(ng/ml)	Insulin resistance (ng/ml)
<b>Group 1</b>			
No.	25	25	25
Range	74 -106	2.1 – 28	0.52 – 6.42
Mean + SD	89.3 + 7.9	17.3 + 6.8	3.77 + 1.4
<b>Group 2</b>			
No.	28	28	28
Range	50 – 120	5.6 – 25.1	2.03 – 7.43
Mean + SD	86.8 + 13.9	16.5 + 5.1	3.67 + 1.3
<b>Group 3</b>			
No.	29	29	29
Range	75 – 99	3.3 – 49	0.67 – 11.23
Mean + SD	84.2 + 6.2	18.8 + 11.7	4.08 + 2.8
<b>P value</b>			
<b>G1 : G2</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>
<b>G2 : G3</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>
<b>G1 : G3</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>

**Table 3:** Statistical analysis of blood glucose, insulin and insulin resistance levels in different groups.

mg/dl), (84.2 ± 6.2 mg/dl) & (89.3 ± 7.9 ng/ml) for glucose, (16.5 ± 5.1 µU/ml, (18.8 ± 11.7 µU/ml) & (17.3 ± 6.8 µU/ml) for insulin, and (3.67 ± 1.3 µU/ml), (4.08 ± 2.8 µU/ml) & (3.77 ± 1.4 µU/ml) for insulin resistance concentrations respectively.

Table 4 expresses the levels of cholesterol, HDL cholesterol, LDL cholesterol and triglyceride in all studied groups. The levels of cholesterol concentrations in the sera of studied groups showed no statistically significant difference (p>0.05) between three groups with means of (181.2 ± 17.5 mg/dl) & (179.5 ± 18.6 mg/dl) & (170.6 ± 14.5 mg/dl) respectively. Whereas, the results revealed significant decrease of HDL cholesterol level in over-weight group (G2) and obese group (G3) with a mean of (31.6 ± 4.5 mg/dl) and (30.7 ± 5.9 mg/dl) respectively as compared to normal weight group (G1) (39.5 ± 3.7 mg/dl). There was no significant difference between over-weight group (G2) and obese group (G3).

The levels of LDL cholesterol concentration in the sera of over-weight group (G2), obese group (G3) and normal weight group (G1) showed that no statistically significant difference between three groups with means (112.8 ± 12.8 mg/dl), (105 ± 18.9 mg/dl) & (108.6 ± 13.8 mg/dl) respectively

As regards to triglyceride levels there were highly significantly increased (p<0.05) in both over-weight group (G2) and obese group (G3) with means + SD of (141.9 ± 39.3 mg/dl) and (141.1 ± 57.8 mg/dl) respectively as compared with normal weight group (G1) (93.7 ± 25.6 mg/dl). No statistically difference between over-weight group (G2) and obese group (G3) was observed.

Table 5 represents the concentrations of blood urea in different examined groups. Overall, statistical analysis clarified that the blood urea concentration was increased significantly in obese group (G3) with a mean (29.1 ± 6.8 mg/dl), whereas in over-weight group (G2) a slightly increased was observed with a mean (24.6 ± 5.5 mg/dl) as compared to normal weight group (G1) with a mean (23.9 ± 4.4 mg/dl). While as regard to serum levels of creatinine the statistical analysis revealed that no difference between over-weight group (G2) with a mean (0.77 ± 0.17 mg/dl) and normal weight group (G1) with a mean (0.75 ± 0.16mg/dl). But in case of obese group (G3) we obtained a significantly increased (0.88 ± 0.17 mg/dl),as compared with normal weight group (G1).

Table 6 and Figure 1 showed the correlation between ghrelin with the other studied parameters in the normal weight group. There was

Groups	Cholesterol (mg/dl)	HDL cholesterol (mg/dl)	LDL cholesterol (mg/dl)	Triglycerides (mg/dl)
<b>Group 1</b>				
No.	25	25	25	25
Range	149.8 -210	33– 47	86.9 - 169.1	57.4 – 144.5
Mean + SD	170.6 + 14.5	39.5 + 3.7	108.6 + 13.8	93.7 + 25.6
<b>Group 2</b>				
No.	28	28	28	28
Range	152.1 – 217	32.1 – 44.3	73.2 – 150	150.6 – 232
Mean + SD	181.2 + 17.5	31.6 + 4.5	112.8 + 12.8	141.9 + 39.3
<b>Group 3</b>				
No.	29	29	29	29
Range	145.1 – 213	28 – 43.2	54.2 – 143.2	79.1 – 250.2
Mean + SD	179.5 + 18.6	30.7 + 5.9	105.8 + 18.9	141.1 + 57.8
<b>P value</b>				
<b>G1 : G2</b>	<b>&gt;0.05</b>	<b>&lt;0.05*</b>	<b>&gt;0.05</b>	<b>&lt;0.05*</b>
<b>G2 : G3</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>
<b>G1 : G3</b>	<b>&gt;0.05</b>	<b>&lt;0.001*</b>	<b>&gt;0.05</b>	<b>&lt;0.05*</b>

**Table 4:** Statistical analysis of sera cholesterol, HDL, LDL cholesterol and Triglycerides levels in different studied groups.

Groups	urea concentration(mg/dl)	Creatinine concentration
<b>Group 1</b>		
No.	25	25
Range	17 – 34	0.4 – 1.1
Mean + SD	23.7 + 4.1	0.75 + 0.15
<b>Group 2</b>		
No.	28	28
Range	15 – 36	0.5 – 1.2
Mean + SD	25.6 + 4.7	0.77 + 0.16
<b>Group 3</b>		
No.	29	29
Range	18 – 42	0.6 – 1.3
Mean + SD	29.5- 5.9	0.86 + 0.17
<b>P value</b>		
<b>G1 : G2</b>	<b>&lt;0.05*</b>	<b>&gt;0.05</b>
<b>G2 : G3</b>	<b>&gt;0.05</b>	<b>&gt;0.05</b>
<b>G1 : G3</b>	<b>&lt;0.001*</b>	<b>&gt;0.05</b>

**Table 5:** serum concentrations of urea and creatinine in the different studied groups

Lean	Ghrelin		Leptin	
	(r) value	P- value	(r) value	P- value
Ghrelin	1.000	-----	-0.548	0.010*
Leptin	-0.548	0.010*	1.000	-----
FBS	0.348	0.122	-0.143	0.535
Insulin	-0.379	0.090	0.918	<0.001*
BMI	-0.547	0.010*	0.983	<0.001*
HOMA	-0.313	0.167	0.883	<0.001*


\* Significant at P ≤ 0.05

**Table 6:** Correlation between ghrelin& other parameters in the normal weight group.

a statistically significant negative correlation between ghrelin, leptin, BMI and HOMA i.e., an increase in ghrelin level is associated with a decrease in leptin, BMI and HOMA levels. There was no statistically significant correlation between ghrelin, FBS and Insulin.

While as regards to leptin, there was a statistically significant positive correlation between leptin, Insulin, BMI and HOMA i.e. an increase in leptin is associated with an increase in Insulin, BMI and HOMA. There was no statistically significant correlation between leptin and FBS.


Table 7 and Figure2 showed the correlation between ghrelin with the other studied parameters in the overweight group, there was a



Over-weight	Ghrelin		Leptin	
	(r) value	P- value	(r) value	P- value
Ghrelin	1.000	----	-0.883	<0.001*
Leptin	-0.883	<0.001*	1.000	-----
FBS	-0.337	0.220	0.249	0.372
Insulin	-0.689	0.005*	0.806	<0.001*
BMI	-0.487	0.050*	0.540	0.038*
HOMA	-0.748	<0.001*	0.840	<0.001*

\*: Significant at  $P \leq 0.05$

**Table 7:** Correlation between ghrelin& other parameters in the over-weight group.



statistically significant negative (inverse) correlation between ghrelin, leptin, insulin, BMI and HOMA i.e. an increase in ghrelin is associated with a decrease in leptin, insulin, BMI and HOMA. There was no statistically significant correlation between ghrelin and FBS.


While as regards to leptin, there was a statistically significant positive (direct) correlation between Leptin, Insulin, BMI and HOMA i.e. an increase in Leptin is associated with an increase in Insulin, BMI and HOMA. There was no statistically significant correlation between Leptin and FBS.

Table 8 and Figure 3 showed the correlation between ghrelin with the other studied parameters in the obese group, there was a

Obese	Ghrelin		Leptin	
	(r) value	P- value	(r) value	P- value
Ghrelin	1.000	----	-0.449	0.008*
Leptin	-0.449	0.008*	1.000	-----
FBS	-0.114	0.520	0.095	0.593
Insulin	-0.564	0.001*	0.510	0.002*
BMI	-0.413	0.015*	0.340	0.049*
HOMA	-0.542	0.001*	0.517	<0.002*

\*: Significant at  $P \leq 0.05$

**Table 8:** Correlation between Ghrelin& other parameters in the obese group.



statistically significant negative correlation between Ghrelin, Leptin, Insulin, BMI and HOMA i.e. an increase in Ghrelin is associated with a decrease in Leptin, Insulin, BMI and HOMA. There was no statistically significant correlation between Ghrelin and FBS. While as regards to leptin, there was a statistically significant positive correlation between leptin, insulin, BMI and HOMA i.e. an increase in leptin is associated with an increase in Insulin, BMI and HOMA. There was no statistically significant correlation between leptin and FBS.

## Discussion

We hypothesized that metabolic profile of overweight individuals would consist of relatively lower concentrations of fasting ghrelin and this what we found in our study comparing overweight and obese groups with normal weight control group, also, there was statistically significant negative correlation between ghrelin levels with leptin, BMI and HOMA.

Our results were in agreement with Yada et al. [28] who stated that ghrelin is important in short-term regulation of appetite and energy balance. The clear pre-prandial rise and post-prandial fall in plasma ghrelin levels support the hypothesis that ghrelin acts as an initiator signal for meal consumption in humans. The pre-prandial increase of ghrelin levels was found to initiate meal consumption voluntarily, without time- or food-related cues [29], while the post-prandial ghrelin suppression is proportional to the ingested calorie load [30]. Ghrelin also appears to be involved in the regulation of long-term energy homeostasis. Ghrelin shows orexigenic effect through its action on the hypothalamic appetite-regulating pathways, while in the periphery ghrelin increases adipose tissue accumulation and has a diabetogenic

effect on the liver and pancreas. Adenosine monophosphate-activated protein kinase (AMPK) has been suggested as one of the mediators of ghrelin's effects. Plasma ghrelin levels are dependent on body mass index as well as food intake patterns. Ghrelin levels are in general reduced in obese individuals and in subjects with insulin resistance [31].

Circulating ghrelin induces abdominal obesity, independently of its central orexigenic activity, via GHS-R-dependent lipid retention [32]. In agreement with our results Williams et al. [12] stated that ghrelin levels inversely correlate with body mass index (BMI). Thus, ghrelin levels are reduced in those who are obese compared to normal body weight controls. Evidence suggests that diet-induced obesity causes ghrelin resistance by reducing NPY/AgRP responsiveness to plasma ghrelin and suppressing the neuroendocrine ghrelin axis, in an attempt to limit further food intake [13]. Ghrelin levels have been shown to negatively correlate with factors which are raised in obesity namely, percentage body fat, insulin and leptin levels [11]. In one study ghrelin levels were not related to fat mass or intra-abdominal fat content, but showed strong negative correlation with insulin levels and insulin resistance [33]. However in an MRI study of non-obese and obese adults, ghrelin was negatively correlated with visceral adiposity, fasting insulin, and homeostasis model insulin resistance index. Visceral adiposity showed stronger inverse correlation with ghrelin than subcutaneous fat possibly through hyperinsulinemia, as the negative correlations with insulin resistance were even stronger [34]. Abnormal glucose homeostasis inversely correlated with, and was found to be an independent determinant of, plasma ghrelin levels in obese children and adolescents [35].

Our results showed that higher concentrations of fasting leptin were found in overweight and obese groups compared with normal weight control group; also, there was statistically significant positive correlation between leptin, insulin, BMI and HOMA.

These results were in agreement with Considine et al. [36] who declared that most obese individuals have higher leptin levels than lean individuals and are resistant or tolerant to the effects of leptin. Leptin resistance was first thought to be due to mutations of the leptin receptor and other rare monogenic obesity syndromes. Mutations of other genes downstream of leptin, including POMC and MC4R, also result in an obese phenotype with associated neuroendocrine dysfunction [37]. However, only a few cases of human obesity are due to monogenic syndromes; instead, most instances appear to be multifactorial [38]. First of all, leptin transport across the blood-brain barrier is impaired in obesity. This is partially due to saturation of the transporter by hyperleptinemia, which is associated with obesity, and subsequent decrease in transport activity [39]. Targeting these mechanisms of leptin resistance will be important in the treatment for obesity and has led to development of insulin sensitizers, such as the chemical chaperones [40].

In a study done by Remsberg et al. [41], Comparable associations were noted with leptin and most measures of body composition, suggesting that leptin levels reflect total body fat and are less affected by fat distribution. Their results parallel those reported by other investigators in which leptin levels exhibit relatively stable associations across differing types of localized fat deposits [42]. Reports in the literature differ, however, on these relationships, and these associations may reflect the varying groups studied. For example, associations between leptin, body composition, and fat distribution tend to be stronger among men and weaker in the obese. Their findings suggest that subcutaneous or white adipose tissue in the abdominal region may be the best predictor of circulating leptin [43].

Mueller et al. [44] suggested that insulin has been shown to influence circulating leptin concentrations. Specifically, insulin increases leptin concentrations in rodents, both in cultured adipocytes as well as in vivo [45]. These associations have also been found in humans, at the level of the adipocyte and in the peripheral circulation wherein experimental hyperinsulinemia using clamp techniques results in increased leptin concentrations [46]. The relationship between leptin or ghrelin and insulin is potentially more complex because of the possibility of insulin resistance; where in comparable concentrations in obese individuals would not have the same effect as in leaner persons [47].

## Conclusion

Our results suggest coordinated roles of ghrelin and leptin in the modulation of the obesity and these markers can be of value in assessment of treatment of such cases.

## References

1. Hill JO (2006) Understanding and addressing the epidemic of obesity: an energy balance perspective. *Endocr Rev* 27: 750–761.
2. Kopelman PG (2000) Obesity as a medical problem. *Nature* 404: 635–643.
3. Abolfotouh MA, Soliman LA, Mansour E, Farghaly M, El-Dawaiaty A (2008) Central obesity among adults in Egypt: prevalence and associated morbidity. *East Mediterr Health J* 14: 57–68.
4. Druce M, Bloom SR (2006) The regulation of appetite. *Arch Dis Child* 91: 183–187.
5. Korbonits M, Grossman AB (2004) Ghrelin: update on a novel hormonal system. *Eur J Endocrinol* 151: S67–S70.
6. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. *Nature* 409: 194–198.
7. Kojima M, Kangawa K (2005) Ghrelin: structure and function. *Physiol Rev* 85: 495–522.
8. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. *J Clin Endocrinol Metab* 86: 5992.
9. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. *Diabetes* 50: 2540–2547.
10. Seoane LM, López M, Tovar S, Casanueva FF, Señaris R, et al. (2003) Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. *Endocrinology* 144: 544–551.
11. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, et al. (2001) Circulating ghrelin levels are decreased in human obesity. *Diabetes* 50: 707–709.
12. Williams DL, Grill HJ, Cummings DE, Kaplan JM (2006) Overfeeding-induced weight gain suppresses plasma ghrelin levels in rats. *J Endocrinol Invest* 29: 863–868.
13. Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB (2010) Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. *Endocrinology* 151: 4745–4755.
14. Brennan AM, Mantzoros CS (2006) Drug insight: the role of leptin in human physiology and pathophysiology – emerging clinical applications. *Nat Clin Pract Endocrinol Metab* 2: 318–327.
15. Margetic S, Gazzola C, Pegg GG, Hill RA (2002) Leptin: a review of its peripheral actions and interactions. *Int J Obes Relat Metab Disord* 26: 1407–1433.
16. Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. *J Immunol* 174: 3137–3142.
17. Sinha MK, Ohannesian JP, Heiman ML, Kriaciunas A, Stephens TW, et al. (1996) Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest* 97: 1344–1347.
18. Blüher S, Mantzoros CS (2009) Leptin in humans: lessons from translational research. *Am J Clin Nutr* 89: 991S–997S.
19. Considine RV, Sinha MK, Heiman ML, Kriaciunas A, Stephens TW, et al.

- (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 334: 292-295.
20. Boden G, Chen X, Mozzoli M, Ryan I (1996) Effect of fasting on serum leptin in normal human subjects. *J Clin Endocrinol Metab* 81: 3419-3423.
21. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS (2003) The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. *J Clin Invest* 111: 1409-1421.
22. Gao Q, Horvath TL (2008) Cross-talk between estrogen and leptin signaling in the hypothalamus. *Am J Physiol Endocrinol Metab* 294: E817-E826.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28: 412-419.
24. Foster-Schubert KE, McTiernan A, Frayo RS, Schwartz RS, Rajan KB, et al. (2005) Human plasma ghrelin levels increase during a one-year exercise program. *J Clin Endocrinol Metab* 90: 820-825.
25. Trinder P (1969) Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. *Ann Clin Biochem* 6: 24-26.
26. Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, et al. (2002) Rapid measurement of insulin using the Abbott IMx: application to the management of insulinoma. *Ann Clin Biochem* 39: 513-515.
27. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499-502.
28. Yada T, Dezaki K, Sone H, Koizumi M, Damdindorj B, et al. (2008) Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. *Curr Diabetes Rev* 4: 18-23.
29. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D (2004) Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. *Am J Physiol Endocrinol Metab* 287: E297-E304.
30. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, et al. (2004) Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. *J Clin Endocrinol Metab* 89: 1319-1324.
31. Cummings DE (2006) Ghrelin and the short- and long-term regulation of appetite and body weight. *Physiol Behav* 89: 71-84.
32. Davies JS, Kotokorpi P, Eccles SR, Barnes SK, Tokarczuk PF, et al. (2009) Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. *Mol Endocrinol* 23: 914-924.
33. Purnell JQ, Weigle DS, Breen P, Cummings DE (2003) Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. *J Clin Endocrinol Metab* 88: 5747-5752.
34. Goldstone AP (2004) Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. *Trends Endocrinol Metab* 15: 12-20.
35. Zhu JF, Liang L, Zou CC, Fu JF (2010) Plasma ghrelin levels and polymorphisms of ghrelin gene in Chinese obese children and adolescents. *Ir J Med Sci* 179: 345-349.
36. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 334: 292-295.
37. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, et al. (2007) Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. *N Engl J Med* 356: 237-247.
38. Farooqi S (2007) Insights from the genetics of severe childhood obesity. *Horm Res* 68: 5-7.
39. Vilà R, Adán C, Rafecas I, Fernández-López JA, Remesar X, et al. (1998) Plasma leptin turnover rates in lean and obese Zucker rats. *Endocrinology* 139: 4466-4469.
40. Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, et al. (2009) Enhanced weight loss with pramlintide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. *Obesity (Silver Spring)* 17: 1736-1743.
41. Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K (2002) Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. *Fertility and Sterility* 78: 479-486.
42. Chapman IM, Wittert GA, Norman RJ (1997) Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. *Clin Endocrinol (Oxf)* 46: 175-181.
43. Haffner SM, Gingerich RL, Miettinen H, Stern MP (1996) Leptin concentrations in relation to overall adiposity and regional body fat distribution in Mexican Americans. *Int J Obes Relat Metab Disord* 20: 904-908.
44. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, et al. (1998) Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. *Endocrinology* 139: 551-558.
45. Mizuno TM, Bergen H, Funabashi T, Kleopoulos SP, Zhong YG, et al. (1996) Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. *Proc Natl Acad Sci U S A* 93: 3434-3438.
46. Pratley RE, Ren K, Milner MR, Sell SM (2000) Insulin increases leptin mRNA expression in abdominal subcutaneous adipose tissue in humans. *Mol Genet Metab* 70: 19-26.
47. Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, et al. (1998) Physiological insulinemia acutely modulates plasma leptin. *Diabetes* 47: 544-549.